HERCULES, CA – August 31, 2012 – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostics products, today announced the launch of Liquichek™ Urine Toxicology O series of screening controls, the newest addition to Bio-Rad’s, urine toxicology quality control product portfolio.
Liquichek Urine Toxicology, Levels S1O, S2O, S1O Low Opiate and S2O Low Opiate are prepared from human urine and contain 12 drugs or drug metabolites at levels 20 – 50% below or above commonly used immunoassay drug cutoff levels. Routine use of Liquichek Urine Toxicology O series provides laboratories the ability to monitor precision for a broad range of urine toxicology testing procedures and helps ensure quality on an ongoing basis. The product is supplied in four individual levels in a liquid (frozen) form that can be tested in the same manner as a patient specimen. This product contains Oxazepam which is suitable for testing Benzodiazepine assays.
For more information, please call 1-800-224-6723 or visit
www.biorad.com/toxcontrols
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The company employs over 7,100 people globally and had revenues exceeding $2 billion in 2011. For more information, visit www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.
For more information contact:
Lillian Valletta, Product Manager
Bio-Rad Laboratories, Inc.
949-598-1200
Email: lillian_valletta@bio-rad.com